A one-year follow-up on the effects of raloxifene on thyroid function in postmenopausal women

OBJECTIVEEstrogens increase serum thyroxine-binding globulin (TBG) and total thyroxine (TT4) concentrations. Serum free thyroxine (FT4) concentrations, however, remain normal. Raloxifene (RAL) is a selective estrogen receptor modulator used to treat postmenopausal osteoporosis. Data on the long-term...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Menopause (New York, N.Y.) N.Y.), 2004-03, Vol.11 (2), p.176-179
Hauptverfasser:	Ceresini, Graziano, Morganti, Simonetta, Rebecchi, Isabella, Bertone, Luca, Ceda, Gian Paolo, Bacchi-Modena, Alberto, Sgarabotto, Mariapaola, Baldini, Monica, Ablondi, Fabrizio, Valenti, Giorgio, Braverman, Lewis E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Double-Blind Method Female Follow-Up Studies Humans Middle Aged Osteoporosis, Postmenopausal - blood Osteoporosis, Postmenopausal - drug therapy Postmenopause Raloxifene Hydrochloride - pharmacology Raloxifene Hydrochloride - therapeutic use Selective Estrogen Receptor Modulators - pharmacology Selective Estrogen Receptor Modulators - therapeutic use Thyroid Function Tests Thyroid Gland - drug effects Thyrotropin - blood Thyroxine - blood Thyroxine-Binding Proteins - metabolism Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!